[go: up one dir, main page]

MX2015011623A - Formulacion en polvo que comprende trombina y fibrinogeno. - Google Patents

Formulacion en polvo que comprende trombina y fibrinogeno.

Info

Publication number
MX2015011623A
MX2015011623A MX2015011623A MX2015011623A MX2015011623A MX 2015011623 A MX2015011623 A MX 2015011623A MX 2015011623 A MX2015011623 A MX 2015011623A MX 2015011623 A MX2015011623 A MX 2015011623A MX 2015011623 A MX2015011623 A MX 2015011623A
Authority
MX
Mexico
Prior art keywords
thrombin
feedstock
fibrinogen
liquid
powder
Prior art date
Application number
MX2015011623A
Other languages
English (en)
Inventor
Glen Martyn
Nicola Kim Whitfield
Laurens Adrianus Hendricus Van Pinxteren
Original Assignee
Profibrix Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1304145.4A external-priority patent/GB201304145D0/en
Priority claimed from GBGB1304146.2A external-priority patent/GB201304146D0/en
Priority claimed from GBGB1313909.2A external-priority patent/GB201313909D0/en
Application filed by Profibrix Bv filed Critical Profibrix Bv
Publication of MX2015011623A publication Critical patent/MX2015011623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0052—Mixtures of macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Materials Engineering (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La invención se refiere a composiciones de polvo estéril para uso médico, que comprenden trombina y fibrinógeno, y a métodos para producir el mismo, en donde el polvo de trombina se produce a partir de una materia prima líquida, en donde la materia prima comprende una solución o una suspensión de la trombina, preferiblemente una solución, en donde el polvo es producido por la eliminación de líquido por un proceso seleccionado de secado por atomización aséptica o secado en lecho fluido aséptico, y en donde el polvo resultante de dicha eliminación de líquido de la materia prima exhibe al menos 80% de la potencia de la trombina o actividad de la materia prima líquida, y en donde el polvo de fibrinógeno es producido por la eliminación de líquido de una materia prima, en donde la materia prima comprende una solución o una suspensión de fibrinógeno, preferiblemente una solución, mediante secado por pulverización aséptica o secado en lecho fluido aséptico, y en donde dicha composición es empaquetada como un producto farmacéutico estéril final para uso médico.
MX2015011623A 2013-03-07 2014-03-07 Formulacion en polvo que comprende trombina y fibrinogeno. MX2015011623A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361774125P 2013-03-07 2013-03-07
US201361774143P 2013-03-07 2013-03-07
GBGB1304145.4A GB201304145D0 (en) 2013-03-07 2013-03-07 Powder formulation
GBGB1304146.2A GB201304146D0 (en) 2013-03-07 2013-03-07 Powder formulation
GBGB1313909.2A GB201313909D0 (en) 2013-08-02 2013-08-02 Powder formulation
PCT/EP2014/054477 WO2014135689A2 (en) 2013-03-07 2014-03-07 Powder formulation

Publications (1)

Publication Number Publication Date
MX2015011623A true MX2015011623A (es) 2015-12-17

Family

ID=51492058

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011623A MX2015011623A (es) 2013-03-07 2014-03-07 Formulacion en polvo que comprende trombina y fibrinogeno.

Country Status (11)

Country Link
US (2) US20160015792A1 (es)
EP (1) EP2964252A2 (es)
JP (1) JP2016510059A (es)
CN (1) CN105188740A (es)
AU (1) AU2014224594B2 (es)
BR (1) BR112015017463A8 (es)
CA (1) CA2898922A1 (es)
EA (1) EA201591657A1 (es)
IL (1) IL240902A0 (es)
MX (1) MX2015011623A (es)
WO (1) WO2014135689A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015324028B2 (en) 2014-09-29 2021-04-01 Board Of Regents Of The University Of Nebraska Nanofiber structures and methods of synthesis and use thereof
RU2702740C2 (ru) * 2015-06-10 2019-10-10 Эвоник Рём ГмбХ Способ получения порошка, содержащего белок, представляющий собой фактор свертывания крови человека, и полимер на основе молочной кислоты
IL242984A0 (en) 2015-12-08 2016-02-29 Omrix Biopharmaceuticals Ltd Thrombin microcapsules, their preparation and how to use them
US10159720B2 (en) 2015-12-08 2018-12-25 Omrix Biopharmaceuticals Ltd Thrombin microcapsules, preparation and uses thereof
US10034957B2 (en) 2015-11-06 2018-07-31 Ethicon Llc Compacted hemostatic cellulosic aggregates
US20220111020A1 (en) * 2016-08-15 2022-04-14 Guangzhou Bioseal Biotech Co. Ltd. Hemostatic compositions and methods of making thereof
US11413335B2 (en) 2018-02-13 2022-08-16 Guangzhou Bioseal Biotech Co. Ltd Hemostatic compositions and methods of making thereof
CN107754005B (zh) 2016-08-15 2021-06-15 广州倍绣生物技术有限公司 止血组合物及其制造方法
AU2017335828B2 (en) 2016-09-28 2023-07-13 Board Of Regents Of The University Of Nebraska Nanofiber structures and methods of use thereof
WO2018080692A1 (en) * 2016-10-27 2018-05-03 El Sabahy Mahmoud Fahmy Ali Nanotechnology-based hemostatic dressings
BR102017008027B1 (pt) * 2017-04-18 2022-04-19 Cristália Produtos Químicos Farmacêuticos Ltda Processo de obtenção de biopolímero de fibrina, meios de aplicação do referido biopolímero de fibrina, e processo de aplicação do referido biopolímero de fibrina
US11738116B2 (en) 2017-06-09 2023-08-29 Board Of Regents Of The University Of Nebraska Expanded nanofiber structures comprising electrospun nanofibers and a plurality of holes and methods of making and use thereof
US10194975B1 (en) * 2017-07-11 2019-02-05 Medtronic Advanced Energy, Llc Illuminated and isolated electrosurgical apparatus
AU2018335389B2 (en) 2017-09-19 2023-11-02 Board Of Regents Of The University Of Nebraska Nanofiber structures and methods of use thereof
CN107727587B (zh) * 2017-09-22 2020-06-19 宁波瑞源生物科技有限公司 一种抗凝血酶ⅲ测定试剂盒及其检测方法
CN107875407A (zh) * 2017-12-15 2018-04-06 天津梅花生物医药科技有限公司 一种新型的原料药无菌处理系统
CN108709369A (zh) * 2018-04-20 2018-10-26 大连工业大学 一种超声波喷雾冷冻干燥装置
WO2019209762A1 (en) * 2018-04-23 2019-10-31 Board Of Regents Of The University Of Nebraska Nanofiber microspheres and methods of use thereof
CN109045362A (zh) * 2018-09-11 2018-12-21 余碧芝 胶原蛋白微颗粒及其制备方法和应用
JP7663252B2 (ja) * 2019-10-23 2025-04-16 フィブリアント・ベスローテン・フェンノートシャップ 抗微生物剤および抗微生物治療用アジュバントとしてのフィブリノゲン
CN110947349B (zh) * 2019-12-24 2024-03-15 上海天晓环保工程有限公司 一种用于脱硫废水零排放的微波晶振干燥装置
US20230240992A9 (en) * 2020-08-10 2023-08-03 Ziropa, Inc. Compositions and methods for topical delivery
US11795189B2 (en) 2020-09-21 2023-10-24 University Of Kentucky Research Foundation Formulation and method for spray-drying D-tagatose
CN111956788A (zh) * 2020-09-22 2020-11-20 上海利康瑞生物工程有限公司 一种猪源纤维蛋白原冻干制剂、制备工艺及其应用
CA3193388A1 (en) * 2020-09-24 2022-03-31 Janine-Melanie Potreck Multi-component system
CN112843326B (zh) * 2021-01-26 2022-11-01 上海利康瑞生物工程有限公司 一种纤维蛋白粘合剂速效止血复合粉及其制备方法
CN112972755B (zh) * 2021-03-25 2022-07-05 哈尔滨瀚邦医疗科技有限公司 一种基于猪源纤维蛋白原和凝血酶的生物止血材料的制备方法
AU2022327637A1 (en) * 2021-08-13 2024-01-18 Biotest Ag Fibrinogen compositions and methods of preparation
CN113797325B (zh) * 2021-09-29 2023-11-21 复旦大学 一种基于气流粉碎技术制备止血材料的方法
IL313718A (en) 2021-12-21 2024-08-01 Ethicon Inc Formulation containing fibrinogen and uses thereof
CN118785918A (zh) 2021-12-23 2024-10-15 广州倍绣生物技术有限公司 喷雾干燥的凝血酶
WO2023129802A1 (en) 2021-12-30 2023-07-06 Baxter International Inc. Fibrinogen and thrombin solutions for a fibrin sealant and fibrin sealant kit
AU2023348185A1 (en) * 2022-09-30 2025-02-27 Ferrosan Medical Devices A/S Haemostatic composition
WO2024207176A1 (en) * 2023-04-04 2024-10-10 Guangzhou Bioseal Biotech Co., Ltd. Hemostatic sealant powder for sealing leaks in tissues

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702955B2 (en) * 1996-05-17 1999-03-11 Quadrant Healthcare (Uk) Limited Microparticles and their use in wound therapy
DE19849589C1 (de) * 1998-10-27 2000-06-15 Glatt Process Technology Gmbh Fibrin-Gewebekleber-Formulierung und Verfahren zu dessen Herstellung
US7572769B2 (en) * 1998-12-23 2009-08-11 Csl Behring Gmbh Fibrin adhesive granulate and method for its preparation
US7927626B2 (en) * 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US9827205B2 (en) * 2008-12-12 2017-11-28 Mallinckrodt Pharma Ip Trading D.A.C. Dry powder fibrin sealant
GB0909136D0 (en) * 2009-05-28 2009-07-01 Profibrix Bv Dry powder composition
WO2010136588A2 (en) * 2009-05-28 2010-12-02 Profibrix B.V. Dry powder fibrin sealant
GB0909129D0 (en) * 2009-05-28 2009-07-01 Quadrant Drug Delivery Ltd Dry powder fibrin sealant
US8846105B2 (en) * 2010-01-08 2014-09-30 Profibrix, B.V. Dry powder fibrin sealant
MX344402B (es) * 2010-06-01 2016-12-14 Baxter Int Inc * Proceso para elaborar composiciones hemostaticas secas y estables.
RU2013155713A (ru) * 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран

Also Published As

Publication number Publication date
JP2016510059A (ja) 2016-04-04
AU2014224594B2 (en) 2018-05-10
EA201591657A1 (ru) 2015-12-30
BR112015017463A8 (pt) 2017-11-28
AU2014224594A1 (en) 2015-07-02
CN105188740A (zh) 2015-12-23
CA2898922A1 (en) 2014-09-12
IL240902A0 (en) 2015-10-29
BR112015017463A2 (pt) 2017-07-11
US20160015792A1 (en) 2016-01-21
US20190269764A1 (en) 2019-09-05
WO2014135689A3 (en) 2014-10-30
WO2014135689A2 (en) 2014-09-12
EP2964252A2 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
MX2015011623A (es) Formulacion en polvo que comprende trombina y fibrinogeno.
MX2015003653A (es) Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
WO2016172134A3 (en) Novel compounds
WO2013061309A3 (en) New a-prp medical device & tissue engineering composition, manufacturing machines and process
WO2015019198A3 (en) High potency pancreatin pharmaceutical compositions
TN2014000131A1 (en) Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and use thereof for production of medicaments
MX2014007897A (es) Nuevos derivados de azetidina, composiciones farmaceuticas y sus usos.
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
PH12015502365B1 (en) Bace1 inhibitors
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
PH12017502112A1 (en) Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors
MX2016000480A (es) Composiciones farmaceuticas de pancreatina de alta potencia.
MX2022013952A (es) Pulverizador de acido tranexamico para la artroplastia de rodilla.
MX2015012343A (es) Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
PH12021551396A1 (en) Active ester derivatives of testosterone, compositions and uses thereof
MX2015009348A (es) Composiciones hemostaticas.
MX2018014165A (es) Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion.
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
IN2014DN08294A (es)
SG11201806628UA (en) New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof